NASDAQ$AVXL
Anavex Life Sciences Corp · Q4 2024 earnings
Q4 2024 earnings · · Investor relations
Briefing
AVXL Q4 2024 — AUD 20.0M revenue, 15.00 EPS
FDA”), and other regulatory authorities and financial trends that we believe may affect our financial condition, results. Anavex Life Sciences Corp reported Q4 2024 results. Diluted EPS came in at 15.00. Headline numbers extracted from the Form 10-K press release; narrative is light because this row was processed without an LLM call.
- Revenue: AUD 20.0M.
- Diluted EPS: 15.00.
- Filed on Form 10-K (accession 0001731122-24-002041).
Headline financials
Revenue & EPS history
Anavex · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+0.4%
Avg return
Earnings day
+4.0%
Avg return
5 days after
+7.1%
Avg return
30 days after
43%
28 / 65 earnings
Positive
+26.0%
Q4 2024
Best reaction
-24.8%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -5.9% | +8.4% | — | |
| Q1 2026 | +6.1% | -4.1% | +13.4% | |
| Q4 2025 | +12.4% | +24.4% | +20.8% | |
| Q3 2025 | -4.9% | -12.4% | -15.6% | |
| Q2 2025 | -1.3% | +1.2% | +24.2% | |
| Q1 2025 | +4.9% | +2.8% | +13.8% | |
| Q4 2024 | +26.0% | +40.3% | +15.8% | |
| Q3 2024 | -5.7% | -2.2% | -13.8% | |
| Q2 2024 | +2.7% | +16.2% | +4.3% | |
| Q1 2024 | -1.7% | +6.0% | -5.9% | |
| Q4 2023 | -4.1% | +7.1% | +40.2% | |
| Q3 2023 | +22.0% | +14.8% | +0.4% | |
| Q2 2023 | +11.3% | +8.2% | +9.9% | |
| Q1 2023 | -1.6% | -5.1% | -12.9% | |
| Q4 2022 | -24.8% | +1.3% | -31.1% | |
| Q3 2022 | +1.9% | +1.7% | -12.9% | |
| Q2 2022 | -3.7% | +13.2% | +12.5% | |
| Q1 2022 | +13.9% | +9.2% | -1.2% | |
| Q4 2021 | +8.2% | +13.7% | +8.5% | |
| Q3 2021 | +8.6% | +7.4% | +3.9% | |
| Q2 2021 | +7.3% | +10.6% | +50.0% | |
| Q1 2021 | -3.4% | -3.3% | +2.6% | |
| Q4 2020 | -4.2% | -6.1% | +4.9% | |
| Q3 2020 | -7.7% | -13.7% | -16.4% | |
| Q2 2020 | +4.5% | +18.9% | +17.1% | |
| Q1 2020 | +5.6% | +12.4% | +7.9% | |
| Q4 2019 | -2.0% | +0.4% | +23.8% | |
| Q3 2019 | +5.5% | -0.4% | +12.2% | |
| Q2 2019 | -1.3% | -1.3% | -4.2% | |
| Q1 2019 | +13.0% | +19.2% | +36.1% | |
| Q4 2018 | -3.8% | -10.4% | -5.2% | |
| Q3 2018 | -5.5% | -3.8% | -7.6% | |
| Q2 2018 | -0.9% | +4.5% | +70.0% | |
| Q1 2018 | -8.4% | -11.2% | +4.6% | |
| Q4 2017 | -13.3% | -14.6% | -10.3% | |
| Q3 2017 | -6.3% | -10.0% | +22.1% | |
| Q2 2017 | -3.6% | -0.5% | -1.2% | |
| Q1 2017 | +5.7% | +12.2% | +3.1% | |
| Q4 2016 | -2.8% | -6.2% | -6.2% | |
| Q3 2016 | +22.1% | +9.6% | -0.7% | |
| Q2 2016 | -10.9% | — | — | |
| Q1 2016 | -20.0% | — | — | |
| Q4 2015 | -21.8% | — | — | |
| Q3 2015 | +13.9% | — | — | |
| Q2 2015 | -5.3% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +17.6% | — | — | |
| Q3 2014 | +4.2% | — | — | |
| Q2 2014 | -8.3% | — | — | |
| Q1 2014 | -9.7% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +1.4% | — | — | |
| Q2 2013 | +8.2% | — | — | |
| Q1 2013 | +5.6% | — | — | |
| Q4 2012 | -1.3% | — | — | |
| Q3 2012 | -17.6% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q1 2012 | +14.4% | — | — | |
| Q4 2011 | -3.8% | — | — | |
| Q3 2011 | -0.9% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -1.6% | — | — | |
| Q4 2010 | -0.3% | — | — | |
| Q3 2010 | +0.9% | — | — | |
| Q2 2010 | +1.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro